Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker AMRX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 50,000 | $17.64 | $882.0K Sale | Form 4 ↗ |
| Aug 12, 2026 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 146,403 | $17.51 | $2.6M Sale | Form 4 ↗ |
| Aug 12, 2026 | Jason B. Daly EVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 210,000 | $17.40 | $3.7M Sale | Form 4 ↗ |
| Aug 11, 2026 | Jason B. Daly EVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 6,613 | $17.70 | $117.1K Sale | Form 4 ↗ |
| May 11, 2026 | Deborah M. Autor Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 34,819 | $12.94 | $450.6K Sale | Form 4 ↗ |
| Nov 17, 2025 | Ted C. Nark Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 50,000 | $11.72 | $586.0K Sale | Form 4 ↗ |
| Nov 12, 2025 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 131,856 | $11.92 | $1.6M Sale | Form 4 ↗ |
| Aug 27, 2025 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 32,000 | $9.23 | $295.4K Sale | Form 4 ↗ |
| Aug 25, 2025 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 6,340 | $9.50 | $60.2K Sale | Form 4 ↗ |
| Aug 22, 2025 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 114,492 | $9.66 | $1.1M Sale | Form 4 ↗ |
| Aug 20, 2025 | Andrew S. Boyer Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 279,244 | $9.38 | $2.6M Sale | Form 4 ↗ |
| Aug 15, 2025 | Tasos Konidaris Executive Vice President & CFO | AMRX Amneal Pharmaceuticals, Inc. | Sale | 219,159 | $9.43 | $2.1M Sale | Form 4 ↗ |
| Aug 14, 2025 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 71,694 | $9.29 | $666.0K Sale | Form 4 ↗ |
| Aug 14, 2025 | Tasos Konidaris Executive Vice President & CFO | AMRX Amneal Pharmaceuticals, Inc. | Sale | 119,206 | $9.30 | $1.1M Sale | Form 4 ↗ |
| Aug 13, 2025 | Tasos Konidaris Executive Vice President & CFO | AMRX Amneal Pharmaceuticals, Inc. | Sale | 161,365 | $9.22 | $1.5M Sale | Form 4 ↗ |
| Aug 12, 2025 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 50,000 | $9.04 | $452.0K Sale | Form 4 ↗ |
| Aug 12, 2025 | Jason B. Daly EVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 22,000 | $9.05 | $199.1K Sale | Form 4 ↗ |
| Aug 12, 2025 | Andrew S. Boyer Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 33,436 | $9.05 | $302.6K Sale | Form 4 ↗ |
| Jun 16, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 94,906 | $8.02 | $761.1K Sale | Form 4 ↗ |
| Jun 10, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 56,426 | $8.02 | $452.5K Sale | Form 4 ↗ |
| May 16, 2025 | Nikita Shah Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 49,140 | $7.58 | $372.5K Sale | Form 4 ↗ |
| May 12, 2025 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 50,000 | $7.59 | $379.5K Sale | Form 4 ↗ |
| May 5, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 4,900 | $8.00 | $39.2K Sale | Form 4 ↗ |
| May 2, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 3,768 | $8.00 | $30.1K Sale | Form 4 ↗ |
| Apr 1, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 80,000 | $8.30 | $664.0K Sale | Form 4 ↗ |
| Mar 14, 2025 | Tushar Bhikhubhai Patel 10% owner | AMRX Amneal Pharmaceuticals, Inc. | Sale | 5.00M | $8.35 | $41.8M Sale | Form 4 ↗ |
| Mar 6, 2025 | Jason B. Daly EVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 46,936 | $8.73 | $409.8K Sale | Form 4 ↗ |
| Mar 5, 2025 | Andrew S. Boyer Executive Vice President | AMRX Amneal Pharmaceuticals, Inc. | Sale | 125,000 | $8.89 | $1.1M Sale | Form 4 ↗ |
| Mar 5, 2025 | Jason B. Daly EVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 43,064 | $8.88 | $382.4K Sale | Form 4 ↗ |
| Mar 5, 2025 | Tasos Konidaris Executive Vice President & CFO | AMRX Amneal Pharmaceuticals, Inc. | Sale | 100,000 | $8.91 | $891.0K Sale | Form 4 ↗ |
| Mar 5, 2025 | Emily Peterson Alva Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 80,000 | $8.90 | $712.0K Sale | Form 4 ↗ |
| Mar 3, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 80,000 | $8.90 | $712.0K Sale | Form 4 ↗ |
| Feb 3, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 80,000 | $8.14 | $651.2K Sale | Form 4 ↗ |
| Jan 8, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 62,590 | $8.01 | $501.3K Sale | Form 4 ↗ |
| Jan 2, 2025 | Gautam Patel Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 17,410 | $8.01 | $139.5K Sale | Form 4 ↗ |
| Nov 22, 2024 | John Kiely Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 17,058 | $8.38 | $142.9K Sale | Form 4 ↗ |
| Nov 22, 2024 | Deborah M. Autor Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 33,229 | $8.34 | $277.1K Sale | Form 4 ↗ |
| Nov 21, 2024 | Deborah M. Autor Director | AMRX Amneal Pharmaceuticals, Inc. | Sale | 6,771 | $8.41 | $56.9K Sale | Form 4 ↗ |
| Nov 21, 2024 | Jason B. Daly SVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 13,665 | $8.40 | $114.8K Sale | Form 4 ↗ |
| Nov 15, 2024 | Jason B. Daly SVP, Chief Legal Officer | AMRX Amneal Pharmaceuticals, Inc. | Sale | 43,657 | $8.61 | $375.9K Sale | Form 4 ↗ |
40 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:33 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances